Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compounded Testosterone Troches to optimize Health and the Testosterone Controversy

Author(s):  Guth Michael AS

Issue:  May/Jun 2015 - Volume 19, Number 3
View All Articles in Issue

Page(s):  195-203

Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 1
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 2
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 3
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 4
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 5
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 6
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 7
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 8
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Page 9

Download in electronic PDF format for $65

Abstract:  As men age, testosterone levels progressively fall and inflammatory biomarkers increase. The gradual decline in testosterone production with aging, known as andropause, is common and may have deleterious effects on men including decreased overall well-being, increased sarcopenia, increased risk of cardiovascular disease, reduced sexual function, and bone loss. Therefore, it comes as no surprise that an increasing number of men worldwide have begun requesting testosterone replacement therapy from their physicians. Occasionally, physicians discourage male patients from getting testosterone replacement therapy based on a few recent studies indicating the therapy causes cardiovascular events, including myocardial infarctions. Yet, an extensive review of the testosterone replacement therapy literature reveals that the majority of clinical studies show that properly administered testosterone replacement therapy, in which estradiol and dihydrotestosterone levels are also controlled, has no adverse effects on myocardial infarction risk. The current state-of the- art in testosterone replacement therapy comprises compounded testosterone troches; an aromatase inhibitor, such as generic Anastrazole, to control estradiol levels; and a 5a-reductase inhibitor, such as generic Dutasteride or Finasteride, to control dihydrotestosterone. Compounded testosterone troches easily raise serum testosterone levels to the optimal range, are highly cost effective at $82 for a 180-day supply, and provide affordable access to testosterone replacement therapy to millions of men requesting it. Yet, the Blue Cross Blue Shield-associated firms have largely denied requests for coverage of compounded medications, including testosterone troches. Despite data demonstrating strong links between testosterone deficiency and significant comorbid conditions (including Type 2 diabetes and other metabolic syndrome diseases) as well as the health benefits of testosterone replacement therapy, some physicians have been swayed against prescribing testosterone replacement therapy to their aging male patients. The testosterone controversy stems largely from poorly designed clinical studies in which patients were subjected to testosterone replacement therapy without having their estradiol and dihydrotestosterone levels properly controlled.

Related Keywords: Michael A.S. Guth, PhD, JD, men, aging, andropause, androgen deficiency, cholesterol transport, testosterone replacement therapy, estradiol, aromatase inhibitor, dihydrotestosterone, 5-alpha reductase inhibitor, cardiovascular events, risk factors, insurance coverage, formulation, drug cost, dosage forms, controversy, therapeutic monitoring, Blue Cross Blue Shield, reimbursement

Related Categories: FORMULATIONS, HRT, CARDIOLOGY, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, LITERATURE REVIEW

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy
Guth Michael AS
May/Jun 2015
Pg. 195-203

Emerging Evidence for Androgen Replacement Therapy in Aging Men
Bramwell Bethany L
Mar/Apr 2010
Pg. 94-99

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Cutter Christopher B
Jan/Feb 2004
Pg. 16-21

Andropause: New Perspectives
Biundo Bruce
May/Jun 2004
Pg. 175-178

Testosterone Deficiency in Men: New Treatments for Andropause
Biundo Bruce
, Shippen Eugene
Nov/Dec 2000
Pg. 429-431

Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Ruiz Andres D
, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R
Jul/Aug 2011
Pg. 290-300

The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
Nov/Dec 2001
Pg. 462-464

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
Glaser Rebecca L
, York Anne E
Jul/Aug 2019
Pg. 325-339

Hormonal Influences in Prostate Cancer: An Update of a Complex Subject
Biundo Bruce
Mar/Apr 2010
Pg. 100-104

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions